#Targeted Alpha Therapy for Neuroendocrine Tumor | Explore Tumblr Posts and Blogs

jesse-pinkman123 · 3 years

Text

Theranostics Market Size Share Trends Forecast Opportunity Analysis 2026

Global Theranostics Market Drivers:-

Development of novel companion diagnostic tests to be used with available treatment options is expected to boost the global Theranostics Market growth over the forecast period. Leading manufacturers are engaged in introduction of novel companion diagnostic tests in market. For instance, Illumina, Inc. announced launch of the U.S. Food & Drug Administration (FDA) approved extended RAS panel for identification of patients eligible for treatment of metastatic colorectal cancer with Vectibix (panitumumab) in 2017.

Increasing adoption of companion diagnostic tests by laboratories is further expected to foster global theranostics market growth over the forecast period. BloodCenter of Wisconsin's Diagnostic Laboratories started offering Abbott RealTime IDH1 assay for patients with acute myeloid leukemia (AML) in July 2018. Moreover, Cancer Genetics, Inc. started offering FDA approved companion diagnostic Thermo Fisher Scientific's Oncomine Dx Target - the first Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) test in 2017. Laboratory Corporation of America Holdings launched OmniSeq Advance in partnership with OmniSeq for tumor cancers in June 2018.

Partnerships and collaborations by leading manufacturers to develop innovative companion diagnostics is expected to foster global theranostics market growth over the forecast period. For instance, Foundation Medicine, Inc. and Pfizer, Inc. entered into a partnership for development, regulatory support, and commercialization of companion diagnostics (CDx) in January 2018. Moreover, Qiagen, Inc., and Freenome partnered in June 2018, to accelerate the development and commercialization of Next-Generation Sequencing (NGS) tests to enable precision medicine in cancer treatment.

Pierre Fabre and Roche have been working on development of a robust prototype immunohistochemistry assay as a future companion diagnostic test for W0101 (the drug candidate which they are developing together) and extended this collaboration in May 2018. Abbott Laboratories, Inc. collaborated with Celgene Corporation, and Agios Pharmaceuticals, to develop diagnostic tests on Abbott’s m2000 RealTime system that identifies certain genomic mutations associated with acute myeloid leukemia (AML) in 2016. These factors are expected to support global theranostics market growth over the forecast period.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2043

Theranostics involves combination of targeted diagnostic tests with targeted therapy. It is also known as companion diagnostics, integrated medicine, Dx/Rx partnering, and pharmacodiagnostics. Implementation of theranostics into the patient care plan (in case of selected diseases for which diagnostic tests are available along with respective therapy) may turn into personalized therapy, which could further improve medical outcomes.

Theranostics include use of specific diagnostic test, which shows a particular molecular target on a tumor or any other disease causing agent. Any disease pathophysiology involves specific biological pathways, which are targeted with the help of diagnostic tests. Diagnostic images of the particular molecule then identifies presence of the specific mutation or receptors (in case of cancer), which can be targeted with the help of therapeutic agents. This approach avoids trial and error treatment and could be used to offer patient specific treatment at the right time. Accurate dose calibration and precisely targeted approach could highly be useful in management of chronic diseases such as cancer.

For instance, neuro endocrine tumors can be diagnosed to assess extent of disease via PET-CT (Positron Emission Tomography – Computer Tomography) using Ga-68 DOTATOC (a radioactive positron emitter). Ga-68 targets somatostatin receptor (SSTR2) on the tumor cell membrane, and is injected through vein, which travels and binds to the SSTR2 indication the presence of tumor on PET scan. Furthermore, Ga-68 can be replaced by a therapeutic agent to target the tumor.

However, improperly defined regulations for these tests coupled with inadequate reimbursement facilities are expected to hamper growth of the global theranostics market over the forecast period.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/theranostics-market-2043

Global Theranostics Market Regional Insights:-

North America is expected to witness significant growth in the global theranostics market over the forecast period. Presence of leading manufacturers, collaborations, robust research, and development activities, and increasing adoption of companion diagnostics is expected to support global theranostics market growth over the forecast period. Biocartis Group NV and Amgen, Inc. partnered to develop companion diagnostic test for Amgen's drug Vectibix (panitumumab) in 2017. For instance, Genome Canada launched a national initiative for clinical implementation of precision health in June 2018, which would ultimately impact global theranostics market growth over the forecast period.

Asia Pacific theranostics market is expected to witness significant growth over the forecast period, owing to collaborations in the region by global organizations and increasing awareness regarding companion diagnostics. For instance, Qiagen collaborated with Japan based clinical lab testing company, SRL, Inc. for introduction of new companion diagnostics with new drug approvals in August 2018.

Key players of Global Theranostics Market:-

Key players operating in the global theranostics market include Thermo Fisher Scientific, Inc., Beckman Coulter, Inc., Focus Diagnostics, AmeriPath, Inc., Illumina, Inc., F.Hoffmann LA-Roche Ltd., Qiagen NV, Myriad Genetics, Inc., Agilent Technologies, Abbott Laboratories, Foundation Medicine, Inc., and Oxford Cancer Biomarkers, Ltd.

Key Development:-

In 2018, THERADIAG, a company specialized in vitro diagnostics and theranostics entered into partnership agreement with Biogaran to supply its Lisa Tracker kits for Biogaran biosimilar monitoring.

In 2018, Novartis AG, entered into an agreement with Endocyte, a US-based Biopharmaceutical Company which develops targeted therapeutics for cancer treatment.

In 2018 RadioMedix Inc. and AREVA Med LLC, announced the Phase 1 trial for AlphaMedixTM in patients with somatostatin receptor positive neuroendocrine tumors in the U.S. AlphaMedixTM is composed of a somatostatin (SST) analogue radiolabeled with 212Pb, an isotope used for Targeted Alpha-emitter Therapy (TAT).

In 2016, avant diagnostics and Amarantus Diagnostics have signed a letter of intent to acquire theranostics health, a protein analysis service provider.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2043

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

mailto:[email protected]

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

#Theranostics Market Growth #Theranostics Market

0 notes

netrf-org · 5 years

Text

NETRF Announces $2.5 Million in Research to Advance the Treatment of Neuroendocrine Tumors

The Neuroendocrine Tumor Research Foundation (NETRF) continues its aggressive funding of neuroendocrine cancer research with eight new grants totaling $2.5 million. With this newest round of funding, NETRF expands its portfolio to include research into lung neuroendocrine tumors (NETs), which affect about one in four NET patients.

NETRF is the leading private funder of neuroendocrine cancer research, funding more than $22 million in NET research since 2005. NETRF looks for innovative and transformational ideas, such as leveraging findings made in other cancer types to accelerate progress in NETs. The eight new projects explore some of the latest advancements in cancer:

CAR T-cell therapy combined with antibody-drug conjugates

Photodynamic therapy

Deciphering the impact of mutations in key genes in NETs

Improving outcomes by combining biomarkers and radiomics

“Smart” chemotherapy

Novel SSTR2 radioligands

Alpha-particle emitting agents for the treatment of lung NETs

Testing new cancer vaccines on NETs

As a less common cancer, NETs lag behind other cancers for research funding. “Neuroendocrine tumor is a neglected tumor type that doesn’t get its due funding from federal institutions and other organizations,” said George Fisher, MD, PhD, co-chair, NETRF Board of Scientific Advisors.

NETs occur in hormone-producing cells, most commonly forming in the lung, pancreas, and gastrointestinal tract. Despite appearing in different sites, tumors forming in this cell type are classified as neuroendocrine and require different tests and treatments.

“We are searching out the best science, identifying dedicated investigators, and asking the right questions with the singular goal of trying to identify new treatments, and better ways to manage the disease,” said Dan Chung, MD, co-chair, NETRF Board of Scientific Advisors.

Two U.S. cancer centers will receive their first NETRF grant: Roswell Park Comprehensive Cancer Center, Buffalo, NY, and Moffitt Cancer Center, Tampa, FL. Two international organizations will also receive their first NETRF grant: BC Canada, Vancouver, Canada, and Radboud University Medical Center, Nijmegen, Netherlands. Other institutions funded in this grant cycle include the University of Pennsylvania, University of Texas MD Anderson Cancer Center, Stanford University, and the University of California, San Francisco.

“We seek out projects to understand the basic biology of NETs, in addition to research that may be translated from the bench to the clinic to make an impact on patient treatment,” said Elyse Gellerman, NETRF chief executive officer.

The NETRF grant process is a competitive and structured peer-review process, which starts with an annual call for letters-of-intent in late spring. All applications are evaluated by NETRF’s Board of Scientific Advisors. Final approval is made by the NETRF Board of Directors.

As a nonprofit 501(c)(3) organization, NETRF is supported by charitable donations from individuals and foundations. A generous, transformational gift from the Margie and Robert E. Petersen Foundation will fund several of the new projects. Additional philanthropic support has been provided by from the Goldhirsh-Yellin Foundation of Los Angeles and the Karpus Family Foundation of New York.

Physicians and scientist can sign up to be notified of NETRF grant opportunities.

Accelerator Award

Multipronged approaches to develop immunotherapy targeting NETs Xianxin Hua, MD, PhD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA This 4-year study will develop nanobody-directed CAR T-cell therapy with various combinatory approaches in laboratory models to kill NET cells. The research will be carried out in collaboration with Dr. Carl June at the University of Pennsylvania, whose work was integrally involved with the approval of CAR T-cell therapy, a personalized, breakthrough immunotherapy for blood cancer. The multipronged approaches will significantly increase the opportunity to develop efficacious NET-specific immunotherapy.

Investigator Awards

NETcure—shine new light on NET therapy Martin Gotthardt, PhD, Radboud University Medical Center, Nijmegen, Netherlands An international collaboration in Spain and the Netherlands will explore photodynamic therapy. The team will develop a “photosensitizer,” which is a molecule that upon activation with light induces cell death. The photosensitizer will be coupled with peptides that bind to neuroendocrine tumor cells. The therapy will then be tested and optimized in laboratory models.

Understanding the physiologically relevant functions of DAXX Guillermina (Gigi) Lozano, PhD, M.D. The University of Texas MD Anderson Cancer Center, Houston, TX To build upon an earlier discovery made by NETRF-funded research, investigators will explore the role of DAXX genomic mutations in pancreatic NETs. First, researchers will study the normal functions of the DAXX gene in laboratory models, then evaluate what happens when the gene is removed. This knowledge can help to identify therapeutic targets.

New strategies to improve drug development for carcinoid tumors Emily Bergsland, MD, University of California, San Francisco, CA Incorporating serial blood samples and CT scan images from a recently clinical trial, a team of investigators from around the country will explore new approaches to monitoring response: evaluation of multiple proteins in circulating blood, and computational analysis of CT images. This very novel work could lead to the identification of better ways of assessing treatment effects, facilitating testing of the next generation of therapeutic agents in NETs.

Pilot Awards

NET-smart chemotherapy: a targeted prodrug strategy Justin Annes, MD, PhD, Stanford University, Stanford, CA By taking advantage of unique properties of NETs that are not found in healthy cells, researchers will try to target chemotherapy to attack only cancer cells, instead of all cells. Creating novel chemotherapeutic agents that will attack and kill only NET cells will help reduce the side effects of currently used systemic chemotherapy.

Novel radioligands to improve radiotherapy of NETs Kuo-Shyan Lin, PhD, BC Cancer, Vancouver, Canada Scientists will explore a novel, very stable compound that binds to NET cells’ somatostatin receptors (SSTR2) more tightly than lutetium 177 dotatate (Lu-177). This new radiotherapeutic isotope will be compared with Lu-177 in disease models. Researchers hope tighter binding of this radiotherapeutic agent to cancer cell receptors will lead to higher radiation accumulation and improved cancer response.

Evaluation of 225Ac-dotatate for treatment of lung carcinoid tumors David Morse, PhD, Moffitt Cancer Center, Tampa, FL Researchers will test a novel radiotherapy, 225Ac-dotatate, a derivative of lutetium 177 dotatate, in PRRT for lung NETs in laboratory models. This therapy emits alpha (α) particles instead of beta (β). Alpha particles are bigger, higher powered, with a shorter reach, which researchers hope will be more effective in killing lung NET cells with decreased toxicity in surrounding normal tissues. Laboratory tests will help evaluate the therapy’s safety and efficacy to prepare for potential testing in humans.

Phase 1 study of SurVaxM

in survivin-positive NETs Renuka Iyer, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY This study tests the immunotherapy SurVaxM in combination with a somatostatin analog in patients with survivin-expressing NETs. The vaccine targets survivin, a protein that’s often highly expressed in lung, intestinal, and pancreatic NETs and associated with aggressive disease because of its ability to prevent tumor cell death. Many patients with incurable brain cancers on SurvaxM have shown better outcomes than would be expected with standard of care alone.

http://bit.ly/2DaZTvi

from WordPress https://netrf.wordpress.com/2019/02/05/netrf-announces-2-5-million-in-research-to-advance-the-treatment-of-neuroendocrine-tumors/

#Uncategorized #NET Research Foundation

0 notes

marketresearchreports07-blog · 6 years

Text

Research Deliver Insight into Nuclear Medicine Market

Over the past 50 years nuclear medicine field has displayed a strong link between investments in chemistry and development of radionuclides and radio-labeled compounds which has impacted the healthcare practice. Nuclear medicine comprises diagnostic and therapeutic techniques that use radioisotopes for applications like oncology, cardiovascular and neurological disorders to provide information at both molecular and cellular level for probing, tracking tissue function, study disease progression and assessing treatment responses.

Request Sample Report at https://www.wiseguyreports.com/sample-request/3288101-nuclear-medicine-radiopharmaceutical-global-market-forecast-to-2024

The nuclear medicine global market is estimated to reach $9,367.8 million by 2024 growing at mid single digit CAGR. Increased radioisotopes applications, rise in public awareness, use of SPECT/CT and PET/CT imaging scans, abundance of radiopharmaceuticals, advancement in imaging technology (hybrid imaging) and alpha therapy based targeted cancer treatment is boosting nuclear medicine market growth. In addition, increasing need in emerging markets, production of radiopharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes and replacement of old/traditional equipments are the opportunities likely to propel the growth of nuclear medicine market.

Nuclear medicinal market is classified based on modality into diagnosis-therapeutics. Diagnostics market held the largest market revenue in 2017 and is expected grow at single digit CAGR due to increase in SPECT and PET procedures. The therapeutics segment is expected to be the fastest growing segment at high double digit CAGR from 2017 to 2024 due to technological advancements in targeted treatment of cancers. Potential new radioisotopes in pipeline and advancement in neurological treatments are the key factors driving the growth of the therapeutics market. Diagnosis by products is segmented into SPECT and PET. SPECT market held the largest market due to increase in TC-99m isotope applications and product approvals. SPECT is segmented based on isotopes into Technetium (Tc-99m), Thallium (Tl-201), Gallium (Ga-67), Iodine (I-123), Samarium (Sm-153), Yttrium (Y-90), Rhenium (Re-186) and others. Technetium (Tc-99m) accounted for largest share in 2017 and is the fastest growing market with projected single digit CAGR growth during 2017 to 2024 due to increase in approvals of Tc-99m based cold kits for different applications. SPECT market by application is segmented into cardiology, pulmonary, oncology, nephrology, neurology, inflammation, thyroid gland, lymphology and others. Cardiology accounted for largest share in 2017 and remains fastest growing market due to increase in number of cardiac imaging cases using Tc-99m.

PET is the fastest growing segment at mid single digit CAGR from 2017 to 2024 due to increase in adoption of cyclotron for production of PET isotopes increasing its availability. The PET isotopes include Fluorodeoxyglucose (18F-FDG), Gallium (Ga-68), Rubidium (Rb-82) and others. The Fluorodeoxyglucose (18F-FDG) accounted for the largest share in 2017and remains the fastest growing market from 2017 to 2024 due to increase in application related to neurology, bone scan, infection and inflammation. PET by applications is segmented into cardiology, oncology, neurology, inflammation and others. Oncology accounted for largest share in 2017 and is the fastest growing market projected to grow with mid single CAGR from 2017 to 2024 due to increase in patient pool of lung cancer, thyroid cancer and breast cancer.

Therapeutic nuclear medicine market is segmented based on radiation type into alpha radiation, beta radiation and brachytherapy. Alpha radiation accounted largest share in 2017 and is the fastest growing market with projected high double digit CAGR from 2017 to 2024 due to new approval of Ra-223 based cold kits by FDA and other regulatory agencies. Beta radiation therapy by isotopes is further segmented into Y-90, I-131, Lu-177, Sm-153, Re-186, Sr-89, Er-169 and others. I-131 held the largest share and is expected to grow at mid single digit CAGR from 2017 to 2024 due to increased use in treatment of thyroid cancer cases. Lu-177 segment was the fastest growing segment at high single digit CAGR from 2017 to 2024 due to increase in approval of Lu-177 based radiopharmaceuticals for treatment of neuroendocrine tumor. Brachytherapy isotopes are further segmented into I-125, Cs-131, Ir-192, Pd-103 and others. I-125 market accounted the largest share in 2017 and is the fastest growing market with projected CAGR of 3.7% from 2017 to 2024 due to increase in increased use in treatment of lung cancer, prostate cancer, eye related disease (retinoblastoma and eye plaque) and brain cancer. Therapeutic nuclear medicine by application is segmented into prostate cancer, thyroid cancer, liver cancer, gastro-entero-pancreatic-neuroendocrine tumors, metastatic bone cancer, breast cancer and others. Prostate cancer market accounted the largest share in 2017 and is the fastest growing market projected with double digit CAGR growth from 2017 to 2024 due to increase in increased use in treatment of prostate cancer.

Nuclear medicine based on end-user is segmented into hospitals, ambulatory centers, diagnostic centers and others. Hospital accounted the largest share in 2017 and is the fastest growing market projected with CAGR of 7.2% from 2017 to 2024 due to readily availability of cyclotrons for generation of isotope and use of advanced hybrid imaging.

The stable isotope global market is poised to reach $256.9 million by 2024. The Nuclear Medicine market includes stable isotopes which are classified into isotopes and applications. Isotopes considered are carbon (C-13), deuterium (D2), oxygen (O-18), nitrogen (N-15), Sulphur (S-32) and others. Deuterium (D-2) accounted largest share in 2017 and is the fastest growing market with projected low single digit CAGR growth from 2017 to 2024 due to use of deuterium as dietary supplement of deuterium-depleted water which helps to extend survival rate of lung cancer patient via exerting anticancer effect and modification of deuterium leads to development of novel, highly differentiated drugs which have therapeutic applications in diabetic nephropathy, hot flashes, spasticity, neuropathic pain and multiple melanoma. The stable isotope applications market is segmented into diagnostics-therapy, pharmaceutical companies and others. Diagnostics-therapy market commanded the largest market revenue in 2017 and expected to grow at a CAGR of 2.6% due to use in diagnosis and treatment of pancreas, liver and intestine related disorders. The pharmaceuticals is projected to be the fastest growing segment from 2017 to 2024 due to novel developments in utilization of stable isotopes which involve biopolymers, where isotope-labeled species are generated from cells grown on labeled growth media.

Geographical wise, North America is the largest market, with a significant share followed by Europe, Asia-Pacific and Rest of the World. North American region commanded the largest revenue market and expected to grow at mid single digit CAGR. Growing use of SPECT and PET scans, technological advancements in equipment, increased utilization of fusion imaging, alpha radio immunotherapy based targeted cancer treatment and complete availability of radiopharmaceutical has led the market growth in this region. However, Asia-Pacific region is expected to grow at a high single digit CAGR from 2017 to 2024 due to increased public awareness and increase in application.

The nuclear medicine global market is a competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring small companies for product expansion. Some of the key players of the nuclear medicine market are Curium Pharma (France), Bayer AG (Germany), GE Company (U.S.), Cardinal Health (U.S.), Jubilant Life science (India), Lantheus Medical Imaging (U.S.), Novartis International AG (Advanced accelerator) (Switzerland), South African Nuclear Energy Corporation (NTP Radioisotopes SOC Ltd) (South Africa), Siemens AG (Germany) and Fujifilm Holding Corporation (Japan).

The report provides an in depth market analysis of the above mentioned segments across the following regions:

North America

Europe

Asia-Pacific

Rest of the World (RoW)

View Detailed Report at https://www.wiseguyreports.com/reports/3288101-nuclear-medicine-radiopharmaceutical-global-market-forecast-to-2024

Table of Contents

1 EXECUTIVE SUMMARY

2 INTRODUCTION

3 MARKET ANALYSIS

4 NUCLEAR MEDICINE GLOBAL MARKET, BY MODALITY

5 NUCLEAR MEDICINE GLOBAL MARKET, BY END-USERS

6 STABLE ISOTOPES

7 REGIONAL ANALYSIS

8 COMPETITIVE LANDSCAPE

9 MAJOR PLAYER PROFILES

About Us:

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

NORAH TRENT

[email protected]

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

0 notes